CTTH (CTT Pharmaceutical Holdings) Total Assets: $0.09 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is CTT Pharmaceutical Holdings Total Assets?

CTT Pharmaceutical Holdings CTTH -0.13% Total Assets is $0.09 Mil as of Dec. 2025. The stock has 4 warning signs investors should review.

CTT Pharmaceutical Holdings's Total Assets for the quarter that ended in Dec. 2025 was $0.09 Mil.

During the past 12 months, CTT Pharmaceutical Holdings's average Total Assets Growth Rate was -2.70% per year. During the past 3 years, the average Total Assets Growth Rate was -64.50% per year.

During the past 13 years, CTT Pharmaceutical Holdings's highest 3-Year average Total Assets Growth Rate was 361.00%. The lowest was -67.70%. And the median was -8.05%.

Total Assets is connected with ROA %. CTT Pharmaceutical Holdings's annualized ROA % for the quarter that ended in Dec. 2025 was -196.23%. Total Assets is also linked to Revenue through Asset Turnover. CTT Pharmaceutical Holdings's Asset Turnover for the quarter that ended in Dec. 2025 was 0.00.

CTT Pharmaceutical Holdings  (OTCPK:CTTH) Total Assets Explanation

Total Assets is connected with ROA %.

CTT Pharmaceutical Holdings's annualized ROA % for the quarter that ended in Dec. 2025 is

ROA %=Net Income (Q: Dec. 2025 )/( (Total Assets (Q: Dec. 2024 )+Total Assets (Q: Dec. 2025 ))/ count )
=-0.156/( (0.073+0.086)/ 2 )
=-0.156/0.0795
=-196.23 %

Note: The Net Income data used here is one times the annual (Dec. 2025) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

CTT Pharmaceutical Holdings's Asset Turnover for the quarter that ended in Dec. 2025 is

Asset Turnover
=Revenue (Q: Dec. 2025 )/( (Total Assets (Q: Dec. 2024 )+Total Assets (Q: Dec. 2025 ))/ count )
=0/( (0.073+0.086)/ 2 )
=0/0.0795
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

CTT Pharmaceutical Holdings Total Assets Related Terms

CTT Pharmaceutical Holdings Total Assets Historical Data

* Premium members only.

The historical data trend for CTT Pharmaceutical Holdings's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CTT Pharmaceutical Holdings Total Assets Chart

CTT Pharmaceutical Holdings Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec24 Dec25
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 1.66 0.64 0.07 0.09

CTT Pharmaceutical Holdings Semi-Annual Data
Dec99 Dec00 Dec01 Dec02 Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec24 Dec25
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 1.66 0.64 0.07 0.09

CTT Pharmaceutical Holdings Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

CTT Pharmaceutical Holdings's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (A: Dec. 2025 )+Total Liabilities (A: Dec. 2025 )
=0.055+0.031
=0.09

CTT Pharmaceutical Holdings's Total Assets for the quarter that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (Q: Dec. 2025 )+Total Liabilities (Q: Dec. 2025 )
=0.055+0.031
=0.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of $0.09 Mil mean?
CTT Pharmaceutical Holdings (CTTH) has a Total Assets of $0.09 Mil as of Dec. 2025. The total amount of assets as recorded on a company's balance sheet. View historical data on CTT Pharmaceutical Holdings and its competitors.
Is CTT Pharmaceutical Holdings' Total Assets too high?
CTT Pharmaceutical Holdings' current Total Assets is $0.09 Mil.
How does CTT Pharmaceutical Holdings' Total Assets compare to BUDZ and SBFM?
CTT Pharmaceutical Holdings' Total Assets of $0.09 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Drug Manufacturers company?
A good Total Assets depends on the Drug Manufacturers industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on CTT Pharmaceutical Holdings and its competitors. CTT Pharmaceutical Holdings's current Total Assets is $0.09 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CTT Pharmaceutical Holdings stock overvalued right now?
CTT Pharmaceutical Holdings (CTTH) has a current Total Assets of $0.09 Mil. The current Total Assets is $0.09 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For CTT Pharmaceutical Holdings (CTTH), the current Total Assets is $0.09 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CTT Pharmaceutical Holdings Business Description

Address 3853 Northdale Boulevard, Suite 268, Tampa, FL, USA, 33624
CTT Pharmaceutical Holdings Inc specializes in drug delivery systems technology within the pharmaceutical industry. Its focus is on fast-dissolving drug delivery systems through the development of oral delivery thin wafers. The company's technology platform includes the development of oral delivery thin wafers to deliver treatment as an alternative to smoking and ingestion. This technology platform target both the human and veterinarian(pet) markets for treatment of many diseases. The Company believes that its technology will be one of the first to gain use in majorly markets such as pain management and smoking cessation. The Oral Thin Film formulation is protected by patents in the USA, Canada, Europe and many other countries across the world.